← Leaderboards
Stephanie J Lee
Dana-Farber Cancer Institute
$27,273,126
Attributed
$29,537,484
Total exposure
17
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,152,892 · 18
FDA$3,534,762 · 1
By mechanism
R01$13,746,174 · 3
U54$10,309,194 · 9
U01$6,951,857 · 2
P01$3,565,440 · 3
UG1$950,400 · 1
K07$164,589 · 1
Top collaborators
- Joseph A Pidala5 shared
- Steven Pavletic1 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- James D Griffin$8,295,553
- Sandra S Zinkel$4,253,324
- David G. Nathan$5,920,675
- G. Mike Makrigiorgos$8,320,443
- D Gary Gilliland$5,135,266
Others in their field
Top investigators on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,815,122
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$39,678,762
- Bruce R. Blazar · University Of Minnesota$37,193,531
- Megan Sykes · Columbia University Health Sciences$33,587,479
Research focus
AllogenicClinical ResearchEnrollmentUnited States National Institutes Of HealthResearch PersonnelFundingChronic Graft Versus Host DiseaseTransplantationSuccessSyndromeClinical TrialsMorbidity - Disease RateCohortResponseProspectiveHematological DiseaseQuality Of LifeConsensusProgramsImmuneSymposiumFunctional DisorderRare DiseasesImmunosuppressive Agents
Grant awards (72)
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)$876,984
R01 · FY2025 · FD · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$535,000
R01 · FY2025 · CA · contact PI
Core D: Long-Term Follow-Up$418,106
P01 · FY2025 · CA · contact PI
BMT CTN Core - Fred Hutchinson Cancer Center$264,000
UG1 · FY2025 · HL · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$681,867
R01 · FY2024 · CA · contact PI
Core D: Long-Term Follow-Up$418,106
P01 · FY2024 · CA · contact PI
BMT CTN Core - Fred Hutchinson Cancer Center$264,000
UG1 · FY2024 · HL · contact PI
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)$862,342
R01 · FY2023 · FD · contact PI
Biologic correlatives of chronic GVHD onset$839,470
U01 · FY2023 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$727,118
R01 · FY2023 · CA · contact PI
Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site$211,200
UG1 · FY2023 · HL · contact PI
Biologic correlatives of chronic GVHD onset$959,842
U01 · FY2022 · CA · contact PI
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)$870,890
R01 · FY2022 · FD · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$702,180
R01 · FY2022 · CA · contact PI
Core D: Long-term Follow-Up$417,866
P01 · FY2022 · CA · contact PI
Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site$211,200
UG1 · FY2022 · HL · contact PI
Biologic correlatives of chronic GVHD onset$510,220
U01 · FY2021 · CA · contact PI
Core D: Long-term Follow-Up$415,912
P01 · FY2021 · CA · contact PI
Core D: Long-term Follow-Up$327,515
P01 · FY2021 · CA · contact PI
Biologic correlatives of chronic GVHD onset$279,864
U01 · FY2021 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$202,856
R01 · FY2021 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$885,612
R01 · FY2020 · CA · contact PI
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)$488,317
R01 · FY2020 · FD · contact PI
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)$436,229
R01 · FY2020 · FD · contact PI
Core D: Long-term Follow-Up$417,131
P01 · FY2020 · CA · contact PI
Biologic correlatives of chronic GVHD onset$300,605
U01 · FY2020 · CA · contact PI
Biologic correlatives of chronic GVHD onset$993,954
U01 · FY2019 · CA · contact PI
Core D: Long-term Follow-Up$375,125
P01 · FY2019 · CA · contact PI
Core D: Long-term Follow-Up$385,394
P01 · FY2018 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$812,043
R01 · FY2017 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$957,625
R01 · FY2016 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$960,249
R01 · FY2015 · CA · contact PI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)$300,000
U54 · FY2014 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$279,083
R01 · FY2014 · CA · contact PI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)$945,170
U54 · FY2013 · CA · contact PI
Improving Outcomes Assessment in Chronic Graft versus Host Disease$850,326
R01 · FY2013 · CA · contact PI
Longitudinal Study of Immune Mediated Disorders After Allogeneic HCT$538,744
U54 · FY2013 · CA · contact PI
RDCRC Administrative Unit$295,063
U54 · FY2013 · CA · contact PI
RDCRC Administrative Unit$295,061
U54 · FY2013 · CA · contact PI
Training and Career Development Core$138,793
U54 · FY2013 · CA · contact PI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)$1,250,000
U54 · FY2012 · CA · contact PI
Longitudinal Study of Immune Mediated Disorders After Allogeneic HCT$382,256
U54 · FY2012 · CA · contact PI
RDCRC Administrative Unit$209,357
U54 · FY2012 · CA · contact PI
Training and Career Development Core$98,477
U54 · FY2012 · CA · contact PI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)$1,167,500
U54 · FY2011 · CA · contact PI
Improving Outcomes Assessment in Chronic GVHD$717,578
R01 · FY2011 · CA · contact PI
Longitudinal Study of Immune Mediated Disorders After Allogeneic HCT$389,898
U54 · FY2011 · CA · contact PI
RDCRC Administrative Unit$213,547
U54 · FY2011 · CA · contact PI
Training and Career Development Core$100,445
U54 · FY2011 · CA · contact PI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)$1,237,500
U54 · FY2010 · AI · contact PI
Improving Outcomes Assessment in Chronic GVHD$743,098
U01 · FY2010 · CA · contact PI
Longitudinal Study of Immune Mediated Disorders After Allogeneic HCT$357,977
U54 · FY2010 · AI · contact PI
RDCRC Administrative Unit$233,404
U54 · FY2010 · AI · contact PI
Training and Career Development Core$153,516
U54 · FY2010 · AI · contact PI
Improving Outcomes Assessment in Chronic GVHD$59,000
U01 · FY2010 · CA · contact PI
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)$1,250,000
U54 · FY2009 · AI · contact PI
Improving Outcomes Assessment in Chronic GVHD$731,854
U01 · FY2009 · CA · contact PI
Longitudinal Study of Immune Mediated Disorders After Allogeneic HCT$364,666
U54 · FY2009 · AI · contact PI
RDCRC Administrative Unit$235,367
U54 · FY2009 · AI · contact PI
Training and Career Development Core$152,453
U54 · FY2009 · AI · contact PI
Improving Outcomes Assessment in Chronic GVHD$59,000
U01 · FY2009 · CA · contact PI
Improving Outcomes Assessment in Chronic GVHD$711,695
U01 · FY2008 · CA · contact PI
Improving Outcomes Assessment in Chronic GVHD$763,255
U01 · FY2007 · CA · contact PI
Core--Data Management and Specimen Tracking$269,073
P01 · FY2007 · HL · contact PI
Enhancing Doctor-Patient Communication$475,556
R01 · FY2006 · CA · contact PI
Core--Data Management and Specimen Tracking$121,212
P01 · FY2006 · HL · contact PI
Enhancing Doctor-Patient Communication$416,883
R01 · FY2005 · CA
Enhancing Doctor-Patient Communication$119,276
R01 · FY2005 · CA
Enhancing Doctor-Patient Communication$436,483
R01 · FY2004 · CA
Enhancing Doctor-Patient Communication$451,677
R01 · FY2003 · CA
MEDICAL DECISION MAKING IN BONE MARROW TRANSPLANTATION$82,564
K07 · FY2001 · CA
MEDICAL DECISION MAKING IN BONE MARROW TRANSPLANTATION$82,025
K07 · FY2000 · CA